MET and non-small cell lung carcinoma: In this case, afatinib plus crizotinib provided almost a median PFS of 13.5 months, which is much longer than the reported mPFS in previous trials, suggesting this combination regimen may be an alternative treatment for EGFR-TKI resistant NSCLC patients with MET amplification.